Regeneron Pharmaceuticals, Inc.

(NASDAQ Global Select)
Back to all articles
Somewhat Bullish +45

Is Regeneron Stock Riskier Than It Looks?

Drug approval Regulatory submission AI-generated analysis

πŸ“ˆ Regeneron stock returned 45.7% over the past year, significantly outpacing the S&P 500's 13.5% gain.

πŸ’° Fiscal Q3 2026 revenue grew 36.3%, driven largely by collaboration revenue from Sanofi reaching an all-time high of $2.7 billion.

πŸ“‰ Legacy EYLEA sales fell by approximately $2 billion in fiscal 2025 due to biosimilar competition and pricing pressure.

πŸš€ Newer product EYLEA HD sales rose 36.3% in fiscal 2025, reaching $1.64 billion as it captures market share.

⚠️ Management expects legacy EYLEA demand to fall by a low-to-mid-teens percentage in the fourth quarter of fiscal 2026.

πŸ”¬ Regeneron anticipates FDA approval for an EYLEA HD prefilled syringe before year-end to support future growth.

πŸ“Š Combined U.S. sales of EYLEA and EYLEA HD shrank slightly by 1% in Q3 2026 due to the legacy product's decline.

πŸ’Ή The stock trades at 19.6 times trailing profit, which is below the S&P 500 average of 22.8x.

πŸ‘€ Investors are awaiting combined U.S. sales data for EYLEA and EYLEA HD expected in January 2027.

Bullish Signals
  • Regeneron stock delivered a massive 45.7% return from November 3, 2025 to November 4, 2026, vastly outperforming the S&P 500.
  • Collaboration revenue with Sanofi on Dupixent reached an all-time high of $2.7 billion in fiscal Q3 2026, driving overall growth.
  • The EYLEA HD product line demonstrated strong resilience with sales rising 36.3% to $1.64 billion in fiscal 2025.
  • Management is optimistic about receiving FDA approval for an EYLEA HD prefilled syringe before the end of the year, which could sustain growth through 2027.
Risk Factors
  • Legacy EYLEA sales declined by approximately $2 billion in fiscal 2025 due to intense competition from biosimilar launches.
  • Management expects demand for the legacy EYLEA product to fall by a low-to-mid-teens percentage in the fourth quarter of fiscal 2026.
  • Combined U.S. sales of the EYLEA franchise shrank by 1% in fiscal Q3 2026 as the decline in legacy EYLEA offset gains from EYLEA HD.
  • The company faces ongoing pricing pressure on its products, which is acting as an offset to growth in the EYLEA HD segment.
Full Analysis
Regeneron Pharmaceuticals (REGN) stock has significantly outperformed the broader market, returning 45.7% from November 3, 2025 to November 4, 2026 compared to the S&P 500's 13.5%. This strong performance coincides with robust overall revenue growth of 36.3% in fiscal Q3 2026. However, this aggregate growth masks a sharp divergence within the company's core ophthalmology franchise, specifically regarding its blockbuster drug EYLEA. The primary driver of Regeneron's recent financial strength is collaboration revenue from Sanofi related to Dupixent, which reached an all-time high of $2.7 billion in fiscal Q3 2026. This segment effectively offset a decline in the legacy EYLEA product, whose sales fell by approximately $2 billion in fiscal 2025 due to increasing competition from biosimilar launches. Despite this headwind, the newer formulation EYLEA HD has surged, with sales rising 36.3% to $1.64 billion in fiscal 2025. Management anticipates that demand for the legacy EYLEA product will decline further by a low-to-mid-teens percentage in the fourth quarter of fiscal 2026 due to pricing pressure and biosimilar competition. To mitigate this risk, Regeneron is optimistic about receiving FDA approval for a prefilled syringe for EYLEA HD before the end of the year, which is expected to sustain growth in 2027 and beyond. The company's stock currently trades at a valuation below the S&P 500 average despite its recent price appreciation. Analysts are closely watching the combined U.S. sales figures for EYLEA and EYLEA HD, which Regeneron is expected to report in January 2027. While the legacy product faces existential threats from biosimilars, the company's strategic pivot toward high-growth collaborations and new delivery formats suggests a complex but potentially resilient financial outlook.